AHCYP2

Across TCGA pan-cancer cohorts, AHCYP2 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of AHCYP2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where AHCYP2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types AHCYP2 is over-expressed in tumor, although a few such as BLCA and KICH show the opposite, repressed pattern.

KIRC, HNSC, and BLCA are the cancer types where AHCYP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AHCYP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.090	<.001	8	view →
HNSC	All	III,IV	+0.051	.004	8	view →
BLCA	Male	IV	−0.657	.002	5	view →
COAD	All	II,III,IV	+0.275	.001	5	view →
KICH	All	All	−0.090	.021	2	view →
PRAD	All	All	−0.056	.020	2	view →
LIHC	All	II,III,IV	−0.178	.024	1	view →
KIRP	Female	All	+0.129	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

AHCYP2–KIRC

Open the KIRC breakdown →